Assembly Biosciences (V7B) Price & Analysis

3 Followers

V7B Stock Chart & Stats

€28.80

-€0.40(-1.82%)

At close: Jul 30 4:00 PM EDT

€28.80

-€0.40(-1.82%)

Day’s Range― - ―

52-Week Range€17.00 - €33.50

Previous CloseN/A

Volume0.00

Average Volume (3M)169.00

Market Cap

€633.09M

Enterprise Value€200.09

Total Cash (Recent Filing)€320.36M

Total Debt (Recent Filing)€2.35M

Price to Earnings (P/E)66.5

Beta0.65

Next Earnings

Nov 11, 2026

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.55

Shares Outstanding20,360,596

10 Day Avg. Volume214

30 Day Avg. Volume169

Financial Highlights & Ratios

PEG Ratio0.67

Price to Book (P/B)1.84

Price to Sales (P/S)5.27

P/FCF Ratio-9.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€42.64

Price Target Upside48.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.99

Revenue Forecast (FY)€44.93M

Bulls Say, Bears Say

Bulls Say

Strong Capitalization And Low LeverageMinimal debt relative to the equity base limits financing risk and preserves flexibility to fund clinical programs. The expanded asset and equity base gives Assembly greater resilience while it advances development without substantial debt-service constraints.

Broader ABI-6250 Pipeline OpportunityExtending ABI-6250 across multiple serious liver diseases increases the program’s commercial and development optionality. The targeted indications have limited treatment options, while planned Phase 2 studies provide defined catalysts for validating the platform.

Substantial Funding For Clinical DevelopmentThe sizable capital raise strengthens Assembly’s ability to execute its clinical strategy and reduces near-term dependence on additional financing. Participation from healthcare-focused investors, including Gilead Sciences, also supports access to development capital.

Bears Say

Persistent Operating And Free Cash OutflowsAssembly remains dependent on external capital because research and clinical operations consume substantial cash. Although the burn improved from earlier periods, negative operating and free cash flow means the business is not yet self-funding.

No Commercial Product RevenueWithout an approved commercial product, recurring revenue remains uncertain and depends on collaboration payments, milestones or future royalties. This leaves financial performance exposed to development outcomes and continued access to external financing.

Operating Profitability Remains UnprovenNear-breakeven net income has not yet translated into sustainable operating profitability. Negative EBIT and EBITDA, combined with volatile results, make long-term earnings difficult to forecast and increase dependence on successful pipeline progression.

Assembly Biosciences News

Assembly Biosciences price target raised to $53 from $45 at Mizuho

Mizuho analyst Salim Syed raised the firm’s price target on Assembly Biosciences (ASMB) to $53 from $45 and...

4d ago

ASMB

Assembly Biosciences initiated with a Buy at UBS

UBS initiated coverage of Assembly Biosciences (ASMB) with a Buy rating and $52 price target The company has...

4d ago

ASMB

Assembly Biosciences reports Q2 EPS (20c), consensus (52c)

Reports Q2 revenue $13.37M, consensus $6.45M. “During the second quarter, we advanced several important strategic priorities, including expanding...

20d ago

ASMB

Assembly Biosciences: Strategic Pipeline Expansion, Strong Cash Position Support Unchanged $50 Price Target and Buy Rating

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Assembly Biosciences. The associated price target...

18d ago

ASMB

Assembly Biosciences Inc (ASMB) Q2 Earnings Cheat Sheet

Assembly Biosciences Inc (ASMB) is scheduled to report 2nd quarter earnings on 08/12/2026. Regarding Q2 estimates, Wall Street...

26d ago

ASMB

Assembly Biosciences price target raised to $45 from $40 at Mizuho

Mizuho raised the firm’s price target on Assembly Biosciences (ASMB) to $45 from $40 and keeps an Outperform...

3M ago

ASMB

Assembly Biosciences Expands Equity Plans, Reelects Board

Assembly Biosciences ( ($ASMB) ) has shared an announcement. At its annual meeting of stockholders on June 4,...

3M ago

ASMB

Assembly Biosciences Completes Significant Equity Offering Financing

Assembly Biosciences ( ($ASMB) ) has issued an update. On May 21, 2026, Assembly Biosciences entered an underwriting...

3M ago

ASMB

Assembly Biosciences Expands ABI-6250 Liver Disease Program

Assembly Biosciences ( ($ASMB) ) has provided an announcement. On May 22, 2026, Assembly Biosciences announced that it...

4M ago

ASMB

Assembly Biosciences announces expansion of ABI-6250 clinical development

Assembly Biosciences (ASMB) announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for...

4M ago

ASMB

Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Assembly Biosciences today and set a price target...

4M ago

ASMB

Assembly Biosciences reports Q1 EPS (54c), consensus (64c)

Reports Q1 revenue $8.21M, consensus $6.95M. “The first quarter reflected steady progress across our portfolio as we continue...

4M ago

ASMB

ASMB Earnings this Week: How Will it Perform?

Assembly Biosciences Inc (ASMB) is scheduled to report 1st quarter earnings on 05/07/2026. Regarding Q1 estimates, Wall Street...

4M ago

ASMB

Assembly Biosciences price target raised to $43 from $39 at Guggenheim

Guggenheim raised the firm’s price target on Assembly Biosciences (ASMB) to $43 from $39 and keeps a Buy...

5M ago

ASMB

GILD

V7B FAQ

What was Assembly Biosciences’s price range in the past 12 months?

Assembly Biosciences lowest stock price was €17.00 and its highest was €33.50 in the past 12 months.

What is Assembly Biosciences’s market cap?

Assembly Biosciences’s market cap is €633.09M.

When is Assembly Biosciences’s upcoming earnings report date?

Assembly Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 67 days.

How were Assembly Biosciences’s earnings last quarter?

Assembly Biosciences released its earnings results on Aug 13, 2026. The company reported -€0.172 earnings per share for the quarter, beating the consensus estimate of -€0.624 by €0.451.

Is Assembly Biosciences overvalued?

According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Assembly Biosciences pay dividends?

Assembly Biosciences does not currently pay dividends.

What is Assembly Biosciences’s EPS estimate?

Assembly Biosciences’s EPS estimate is -0.56.

How many shares outstanding does Assembly Biosciences have?

Assembly Biosciences has 20,360,596 shares outstanding.

What happened to Assembly Biosciences’s price movement after its last earnings report?

Assembly Biosciences reported an EPS of -€0.172 in its last earnings report, beating expectations of -€0.624. Following the earnings report the stock price went up 19.87%.

Which hedge fund is a major shareholder of Assembly Biosciences?

Currently, no hedge funds are holding shares in DE:V7B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Assembly Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

309.55%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Assembly Biosciences (V7B) Earnings & Revenues

Historic Earnings Reports

V7B Stock 12 Month Forecast

Average Price Target

€42.64

▲(48.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","46":"€46","25.75":"€25.8","32.5":"€32.5","39.25":"€39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45.65207099,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€45.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.637311585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€42.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.03847269,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€37.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,25.75,32.5,39.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.1,30.37323623,31.646472460000002,32.91970869,34.19294492,35.46618115,36.73941738,38.01265361,39.285889839999996,40.55912607,41.8323623,43.105598529999995,44.37883476,{"y":45.65207099,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.1,30.141331660384616,31.182663320769233,32.22399498115385,33.265326641538465,34.30665830192308,35.34798996230769,36.38932162269231,37.43065328307692,38.471984943461536,39.51331660384615,40.55464826423077,41.595979924615385,{"y":42.637311585,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.1,29.710651745384617,30.321303490769232,30.931955236153847,31.542606981538462,32.15325872692308,32.76391047230769,33.37456221769231,33.98521396307692,34.59586570846154,35.20651745384615,35.81716919923077,36.427820944615384,{"y":37.03847269,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.1,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >